134 related articles for article (PubMed ID: 32550993)
1. Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines.
Sato M; Fuchida H; Shindo N; Kuwata K; Tokunaga K; Xiao-Lin G; Inamori R; Hosokawa K; Watari K; Shibata T; Matsunaga N; Koyanagi S; Ohdo S; Ono M; Ojida A
ACS Med Chem Lett; 2020 Jun; 11(6):1137-1144. PubMed ID: 32550993
[TBL] [Abstract][Full Text] [Related]
2. Deciphering the Mechanism of Binding Selectivity of Chlorofluoroacetamide-Based Covalent Inhibitors toward L858R/T790M Resistance Mutation.
Akher FB; Farrokhzadeh A; Ravenscroft N; Kuttel MM
J Chem Inf Model; 2022 Feb; 62(4):997-1013. PubMed ID: 35119858
[TBL] [Abstract][Full Text] [Related]
3. Selective and reversible modification of kinase cysteines with chlorofluoroacetamides.
Shindo N; Fuchida H; Sato M; Watari K; Shibata T; Kuwata K; Miura C; Okamoto K; Hatsuyama Y; Tokunaga K; Sakamoto S; Morimoto S; Abe Y; Shiroishi M; Caaveiro JMM; Ueda T; Tamura T; Matsunaga N; Nakao T; Koyanagi S; Ohdo S; Yamaguchi Y; Hamachi I; Ono M; Ojida A
Nat Chem Biol; 2019 Mar; 15(3):250-258. PubMed ID: 30643284
[TBL] [Abstract][Full Text] [Related]
4. Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors.
Wurz RP; Pettus LH; Ashton K; Brown J; Chen JJ; Herberich B; Hong FT; Hu-Harrington E; Nguyen T; St Jean DJ; Tadesse S; Bauer D; Kubryk M; Zhan J; Cooke K; Mitchell P; Andrews KL; Hsieh F; Hickman D; Kalyanaraman N; Wu T; Reid DL; Lobenhofer EK; Andrews DA; Everds N; Guzman R; Parsons AT; Hedley SJ; Tedrow J; Thiel OR; Potter M; Radinsky R; Beltran PJ; Tasker AS
ACS Med Chem Lett; 2015 Sep; 6(9):987-92. PubMed ID: 26396685
[TBL] [Abstract][Full Text] [Related]
5. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
[TBL] [Abstract][Full Text] [Related]
6. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S.
Lategahn J; Keul M; Klövekorn P; Tumbrink HL; Niggenaber J; Müller MP; Hodson L; Flaßhoff M; Hardick J; Grabe T; Engel J; Schultz-Fademrecht C; Baumann M; Ketzer J; Mühlenberg T; Hiller W; Günther G; Unger A; Müller H; Heimsoeth A; Golz C; Blank-Landeshammer B; Kollipara L; Zahedi RP; Strohmann C; Hengstler JG; van Otterlo WAL; Bauer S; Rauh D
Chem Sci; 2019 Dec; 10(46):10789-10801. PubMed ID: 31857889
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
Xiao Q; Qu R; Gao D; Yan Q; Tong L; Zhang W; Ding J; Xie H; Li Y
Bioorg Med Chem; 2016 Jun; 24(12):2673-80. PubMed ID: 27131639
[TBL] [Abstract][Full Text] [Related]
9. Fragment-Based Discovery of Irreversible Covalent Inhibitors of Cysteine Proteases Using Chlorofluoroacetamide Library.
Miura C; Shindo N; Okamoto K; Kuwata K; Ojida A
Chem Pharm Bull (Tokyo); 2020; 68(11):1074-1081. PubMed ID: 33132374
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC.
Chen L; Fu W; Feng C; Qu R; Tong L; Zheng L; Fang B; Qiu Y; Hu J; Cai Y; Feng J; Xie H; Ding J; Liu Z; Liang G
Eur J Med Chem; 2017 Nov; 140():510-527. PubMed ID: 28987609
[TBL] [Abstract][Full Text] [Related]
11. Selective covalent targeting of SARS-CoV-2 main protease by enantiopure chlorofluoroacetamide.
Yamane D; Onitsuka S; Re S; Isogai H; Hamada R; Hiramoto T; Kawanishi E; Mizuguchi K; Shindo N; Ojida A
Chem Sci; 2022 Mar; 13(10):3027-3034. PubMed ID: 35432850
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
Cheng H; Nair SK; Murray BW; Almaden C; Bailey S; Baxi S; Behenna D; Cho-Schultz S; Dalvie D; Dinh DM; Edwards MP; Feng JL; Ferre RA; Gajiwala KS; Hemkens MD; Jackson-Fisher A; Jalaie M; Johnson TO; Kania RS; Kephart S; Lafontaine J; Lunney B; Liu KK; Liu Z; Matthews J; Nagata A; Niessen S; Ornelas MA; Orr ST; Pairish M; Planken S; Ren S; Richter D; Ryan K; Sach N; Shen H; Smeal T; Solowiej J; Sutton S; Tran K; Tseng E; Vernier W; Walls M; Wang S; Weinrich SL; Xin S; Xu H; Yin MJ; Zientek M; Zhou R; Kath JC
J Med Chem; 2016 Mar; 59(5):2005-24. PubMed ID: 26756222
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR.
Basu D; Richters A; Rauh D
Bioorg Med Chem; 2015 Jun; 23(12):2767-80. PubMed ID: 25975640
[TBL] [Abstract][Full Text] [Related]
15. Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology.
Song X; Liu X; Ding X
J Mol Recognit; 2017 Apr; 30(4):. PubMed ID: 27891677
[TBL] [Abstract][Full Text] [Related]
16. Rational Computational Design of Fourth-Generation EGFR Inhibitors to Combat Drug-Resistant Non-Small Cell Lung Cancer.
Park H; Jung HY; Kim K; Kim M; Hong S
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33297461
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation.
Yan Q; Chen Y; Tang B; Xiao Q; Qu R; Tong L; Liu J; Ding J; Chen Y; Ding N; Tan W; Xie H; Li Y
Eur J Med Chem; 2018 May; 152():298-306. PubMed ID: 29730192
[TBL] [Abstract][Full Text] [Related]
18. Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.
Lelais G; Epple R; Marsilje TH; Long YO; McNeill M; Chen B; Lu W; Anumolu J; Badiger S; Bursulaya B; DiDonato M; Fong R; Juarez J; Li J; Manuia M; Mason DE; Gordon P; Groessl T; Johnson K; Jia Y; Kasibhatla S; Li C; Isbell J; Spraggon G; Bender S; Michellys PY
J Med Chem; 2016 Jul; 59(14):6671-89. PubMed ID: 27433829
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
Song Z; Huang S; Yu H; Jiang Y; Wang C; Meng Q; Shu X; Sun H; Liu K; Li Y; Ma X
Eur J Med Chem; 2017 Jun; 133():329-339. PubMed ID: 28395219
[TBL] [Abstract][Full Text] [Related]
20. Structural pharmacological studies on EGFR T790M/C797S.
Kong LL; Ma R; Yao MY; Yan XE; Zhu SJ; Zhao P; Yun CH
Biochem Biophys Res Commun; 2017 Jun; 488(2):266-272. PubMed ID: 28456628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
